Recurrent Disturbance of Consciousness in a Peritoneal Dialysis Patient with Severe Hypercalcemia Caused by Daily Low-Dose Keto Acids Supplementation

Peng Li, Xiaojing Zhong and Jianying Niu

Abstract

Keto acids is widely used in dialysis patients with end-stage renal disease, which can effectively correct hypocalcemia, reduce blood PTH as well as blood phosphorus, and elevate blood albumin. Keto acids have a very low incidence of side effects. So far, no cases of Keto acids-induced severe hypercalcemia had been reported. The authors here present a case of continuous ambulatory peritoneal dialysis (CAPD) patient who repeatedly developed severe hypercalcemia accompanied by consciousness disturbance due to daily low-dose keto acids administration. In this case, common causes of hypercalcemia were excluded by thorough physical examination and investigations. The blood calcium concentration of this patient had reached 3.83 mmol/L, belonging to severe hypercalcemia, and the clinical manifestations of cognitive disorder required urgent treatment. After the suspension of keto acids, the serum calcium concentration returned to normal, and the peritoneal dialysis scheme resumed as normal after discharge, which could still maintain the normal calcium concentration. When the patient took the medicine again, severe hypercalcemia occurred as expected. After drug withdrawal, blood calcium backed to normal level, and blood phosphorus increased, which further confirmed that calcium and phosphorus metabolism disorder was closely related to the use of keto acids. This case here indicate that close monitoring of blood calcium, phosphorus and other indicators are needed, in order to prevent potential risk of hypercalcemia which would endanger the safety of patient's life.

Keywords: Disturbance of consciousness; Peritoneal dialysis; Hypercalcemia; Keto acids

Introduction

Peritoneal dialysis patients who prescribed a low-protein diet supplemented with keto acids had showed a better preservation of residual renal function (RRF), lower serum phosphorus level, as well as lower intact parathyroid hormone (iPTH) level [1].Moreover, improvements in hs-CRP and the leptin/adiponectin ratio (LAR) in continuous ambulatory peritoneal dialysis (CAPD) patients with Keto acids administration, suggested that metabolic benefit would also achieved by the therapy [2]. However, higher serum calcium levels would be observed during follow-up, as the keto acid tablets contain 50 mg of calcium each. So caution on the possible risk for severe hypercalcemia in CAPD patients treated with keto acids is definitely needed. Considering researches focusing this are limited, in this paper, the author shared a case of CAPD patient who repeatedly developed severe hypercalcemia accompanied by consciousness disturbance due to taking daily low-dose keto acids.

Case Report

A 73-year-old Chinese non-diabetic female patient (74 kg) was admitted in July 2017 because of an altered level of consciousness for one week. The patient was a known case of chronic kidney disease 5 years ago and treated with CAPD (Tenckhoff double-cuff catheter) for 3 years. She also had histories of hypertension, and a transient ischemic attack in 2014. She also had histories of hypertension, and a transient ischemic attack in 2014.

The patient was a known case of chronic kidney disease 5 years ago and treated with CAPD (Tenckhoff double-cuff catheter) for 3 years. She also had histories of hypertension, and a transient ischemic attack in 2014.

There is no prior history of catheter infection, CAPD peritonitis. Her PD regimen was: 1.5% Low calcium (1.25 mmol/L) dextrose dialysate (Dianeal®; Baxter Ltd, Guangzhou, China) 2L (4h*1 time) +2.5% Low calcium dextrose dialysate2L (4h*2 times) with Twin Bag system (UltraBag®; Baxter China Ltd). Her existing list of regular oral medications included amlodipine 5 mg daily, atorvastatin 20 mg daily, keto acids (Ketosteril®; Fresenius-Kabi Co., Ltd, Beijing, China) 2,520 mg with three meals, without taking active vitamin D and calcium-containing phosphorus binder. On presentation, her blood pressure was 134/75 mm of Hg, pulse rate 84 per minute, and core temperature 97.7 degrees Fahrenheit. Pupils were 4 millimeters in size, equal, with no scleral icterus or conjunctivitis. Cardiac exam revealed no jugular venous distention, tachycardia or murmurs. Lungs were clear to auscultation bilaterally. Abdomen was soft with normal bowel sounds and no hepatosplenomegaly. Extremities were without peripheral edema. There were no definite focal neurologic signs in the patient and the Glasgow Coma Score was 9. The preliminary laboratory findings were: serum creatinine 8.33 mg/dL, serum urea nitrogen 55.57 mg/dL, serum adjusted calcium 3.30 mmol/L, serum phosphorus 1.05 mmol/L, serum albumin 44.8 g/L, serum potassium 3.4 mmol/L, serum magnesium 1.46 mmol/L, serum iPTH 33.9 pmol/L, blood hemoglobin 142 g/L, blood platelet count 145,000/μL. The Kt/V total was 1.63/week. There was no abnormality detected in the computed tomography (CT) of the brain.

Treatment to improve the adequacy of peritoneal dialysis, and increase calcium efflux from PD fluid, her PD regimen was adjusted to: 1.5% Low calcium (1.25 mmol/L) dextrose dialysate 2L (4 h*2 times) +2.5% Low calcium dextrose dialysate 2L (4 h*2 times)+1.5% low calcium dextrose dialysate 2L overnight. Keto acids administration was...
stopped and 500 mL of normal saline was dropped daily. After treatment, the patient showed improvement in reaction retardation, fatigue and mental malaise. After 4 days of hospitalization, test results were as follows: serum adjusted calcium 2.91 mmol/L, serum phosphorus 1.32 mmol/L, serum magnesium 1.45 mmol/L. The patient and her family refused further test to determine the cause of hypercalcemia. Therefore, the patient was discharged from the hospital. Two weeks after discharge, the test results: blood calcium 2.47 mmol/L, blood phosphorus 2.19 mmol/L. But one month after discharge, the patient was admitted again for fatigue and slow reaction for 1 day. The patient's family member had given her keto acids 2,520 mg with three meals again. The serum calcium was over 3.49 mmol/L in the emergency room. Her PD regimen was immediately adjusted to: 1.5% Low calcium dextrose dialysate 2L (3h*5 times). A single 50IU dose of salmon calcitonin intramuscular injection daily and 500 ml of normal saline daily were given to treat hypercalcemia. The next day, the serum adjusted calcium was 3.83 mmol/L, and serum phosphorus was 0.43 mmol/L. Other detailed examination results were: iPTH 43.4 pmol/L, 25 hydroxy vitamin D 11.02 nmol/L, calcitonin 7.4 pg/mL. Tumor markers (AFP, CEA, CA125, NSE, CA153, CA50, CA211, CA242) were normal. No obvious abnormalities were observed in 99mTc-MIBI static imaging of parathyroid gland. Examination results on the fourth day after admission were: serum calcium 2.35 mmol/L. The patient returned to normal without symptoms of fatigue and slow reaction and was discharged from hospital.

Follow-up after discharged from hospital, the patient's serum calcium was maintained at 2.48 mmol/L –2.6 mmol/L during long-term follow-up (Figure 1 for the changes of serum calcium and phosphorus value).

![Figure 1: Changes of serum calcium and phosphorus value.](image)

**Discussion**

Keto acids have a very low incidence of side effects and no cases of Keto acids-induced severe hypercalcemia had been reported in literature before. If hypercalcemia occurs, it is recommended to reduce vitamin D intake. When hypercalcemia persists, reduce the dosage of this product and avoid intake of other calcium-containing substances.

However, the assessment of calcium balance in dialysis patients (including PD patients) becomes extremely complex. It has to take into account not only dietary calcium intake, calcium supplement dose, intake of vitamin D analogs, stool calcium output, calcium uptake by soft tissue, urinary calcium excretion, continuous calcium flux from the exchangeable calcium bone pool, and net bone remodeling or turnover, but also calcium influx and efflux from PD fluid, depending on the dialysate calcium concentration and the amount of calcium removed with dialysis ultrafiltration [3-6].

Hypercalcemia can be diagnosed when blood calcium value is more than 2.6 millimol/L with serum protein concentration in the normal range. If accompanied by hyperalbuminemia, hypoalbuminemia or significantly increased platelet count, ionic calcium should be determined for definite diagnosis and combined with clinical manifestations of hypercalcemia. In this case, the serum albumin and blood platelet count were in the normal range, and pseudohypercalcemia could be excluded. The clinical score of hypercalcemia is as follows: mild (<3.0 mmol/L), often asymptomatic, generally without urgent treatment. Moderate (3.0-3.5 mmol/L), if the increase rate of blood calcium is slow, the patient can often tolerate it, but need prompt treatment. Severe (>3.5 mmol/L), prone to arrhythmia or coma requiring urgent treatment [7]. The blood calcium concentration of this patient had reached 3.83 mmol/L, belonging to severe hypercalcemia, and the clinical manifestations of cognitive disorder required urgent treatment. Of course, clinical manifestations depend not only on calcium concentration, but also on the rate of calcium increase.

After a definite diagnosis, the cause of the disease should be actively sought. Human calcium balance regulation mainly depends on the action of parathyroid hormone, vitamin D and calcitonin on bone, kidney and digestive tract. According to statistics, 90% of hypercalcemia is caused by primary hyperparathyroidism or malignant tumors. Relatively rare causes include: thiazide diuretics, familial low urinary calcium hypercalcemia, non-malignant granulomatous disease, thyrotoxicosis, too much vitamin D, rhabdomyolysis, adrenocortical function decline, hypervitaminosis A, theophylline intoxication, pheochromocytoma, etc. [7].

In our case, common causes of hypercalcemia were excluded by thorough physical examination and investigations. After the elimination of other causes, it was speculated that hypercalcemia was related to the use of keto acids tablets. This medicine contains four kinds of calcium ketone ammonia and one kind of calcium hydroxy ammonia. Each tablet contains 50 mg of calcium which means taking 12 tablets daily would increases the intake of calcium by 600 mg. This is further supported by the fact that no further episodes of consciousness disturbance occurred following keto acids discontinuation. Importantly, no adjustments were made to her other regular oral medications. After the suspension of the drug, the serum calcium concentration returned to normal, and the peritoneal dialysis scheme resumed as normal after discharge, which could still maintain the normal calcium concentration. When the patient took the medicine again, severe hypercalcemia occurred as expected. After keto acids discontinuation, hypercalcemia can be recovered, which also proves that hypercalcemia is related to the medicine. At the same time, when the serum calcium increased significantly after taking this medicine, the serum phosphorus decreased significantly, which is related to the elimination of phosphorus by the drug in the intestinal
tract. After drug withdrawal, blood calcium returned to normal, and blood phosphorus increased, which further confirmed that calcium and phosphorus metabolism disorder was closely related to the use of the drug. These aforementioned factors cumulate in a ‘probable’ rated adverse drug reaction (ADR), assessed objectively by the Naranjo probability algorithm for ADR [8].

Conclusion

Keto acids are widely used in dialysis patients with end-stage renal disease [9,10]. The drug can effectively correct hypocalcemia, reduce blood PTH, elevate blood albumin and reduce blood phosphorus, so as to protect the patient’s residual renal function. However the case here indicate that close monitoring of blood calcium, phosphorus and other indicators are needed, in order to prevent hypercalcemia which would endanger the safety of patient’s life.

Acknowledgement

The authors thank all PD nurses, technicians, and staff in the Department of Renal Division, Shanghai Fifth People’s Hospital, Fudan University, for their contributions.

Author Contributions

Peng Li, Xiaojing Zhong and Jianying Niu were physicians for the patient, and Peng Li wrote the manuscript and carried out final preparation of the manuscript. All authors carried out the literature review and drafted the manuscript. All authors read and approved the final manuscript.

References